The role of adiponectin receptors in the regulation of synaptic transmission in the hippocampus

Weisz, Filippo; Piccinin, Sonia; Mango, Dalila; Ngomba, Richard Teke; Mercuri, Nicola Biagio; Nicoletti, Ferdinando; Nisticò, Robert

doi:10.1002/syn.21964

Cited by 25 publications

(18 citation statements)

References 57 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Furthermore, adiponectin applied 10 minutes prior to stimulation protocols potentiates LTP via high-frequency stimulation and prevents induction of long-term depression (LTD) via low-frequency stimulation, suggesting that adiponectin may play a role in both LTP and LTD. In contrast to the DG, in the cornu ammonis 1 (CA1) region of the hippocampus, the adiponectin receptor agonist AdipoRon reduces LTP [ 112 ], suggesting subregional variation in adiponectin responses. In addition, these studies found subregion-specific alterations in paired pulse facilitation, indicating potential presynaptic mechanisms of adiponectin signaling.…”

Section: Adiponectin and Alzheimer's Diseasementioning

confidence: 99%

Role of Adiponectin in Central Nervous System Disorders

et al. 2018

View full text Add to dashboard Cite

Adiponectin, the most abundant plasma adipokine, plays an important role in the regulation of glucose and lipid metabolism. Adiponectin also possesses insulin-sensitizing, anti-inflammatory, angiogenic, and vasodilatory properties which may influence central nervous system (CNS) disorders. Although initially not thought to cross the blood-brain barrier, adiponectin enters the brain through peripheral circulation. In the brain, adiponectin signaling through its receptors, AdipoR1 and AdipoR2, directly influences important brain functions such as energy homeostasis, hippocampal neurogenesis, and synaptic plasticity. Overall, based on its central and peripheral actions, recent evidence indicates that adiponectin has neuroprotective, antiatherogenic, and antidepressant effects. However, these findings are not without controversy as human observational studies report differing correlations between plasma adiponectin levels and incidence of CNS disorders. Despite these controversies, adiponectin is gaining attention as a potential therapeutic target for diverse CNS disorders, such as stroke, Alzheimer's disease, anxiety, and depression. Evidence regarding the emerging role for adiponectin in these disorders is discussed in the current review.

show abstract

Section: Adiponectin and Alzheimer's Diseasementioning

confidence: 99%

Role of Adiponectin in Central Nervous System Disorders

et al. 2018

View full text Add to dashboard Cite

show abstract

“…Cognitive decline in AD is attributed to synaptic dysfunction in the hippocampus 11 , related to a loss of long-term potentiation (LTP), a molecular mechanism of hippocampal synaptic plasticity 12–14 . Adiponectin treatment was shown to enhance synaptic function 15 and promote presynaptic release 16 , and increases in circulating adiponectin levels alleviate memory dysfunction in models of dementia 5,17 . To evaluate the effects of adiponectin on hippocampal LTP as well as the mobility of cell surface ionotropic glutamate receptors in AD, we utilised a mouse model harbouring five familial AD mutations, the 5XFAD mouse.…”

Section: Introductionmentioning

confidence: 99%

Adiponectin improves long-term potentiation in the 5XFAD mouse brain

Wang

Song

2019

Sci Rep

View full text Add to dashboard Cite

Adiponectin is an adipokine that regulates apoptosis, glucose and lipid metabolism, and insulin sensitivity in metabolic diseases. As recent studies have associated changes in adipokines and other metabolites in the central nervous system with a risk for Alzheimer’s disease (AD), we investigated the effects of adiponectin treatment on hippocampal cells in the 5XFAD mouse model of AD and neuronal SH-SY5Y cells under amyloid beta toxicity. Adiponectin treatment reduced levels of cleaved caspase 3 and nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) apoptosis signalling and decreased glycogen synthase kinase 3 beta (GSK3β) activation. Moreover, adiponectin treatment triggered long-term potentiation in the hippocampi of 5XFAD mice, which was associated with reduced expression of N -methyl- d -aspartate and its receptor as well as surface expression of the α-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptor. These findings suggest that adiponectin inhibits neuronal apoptosis and inflammatory mechanisms and promotes hippocampal long-term potentiation. Thus, adiponectin exhibits beneficial effect on hippocampal synaptic plasticity in Alzheimer’s disease mouse model.

show abstract

“…Furthermore, adiponectin acts using three different receptors: AdipoR1, AdipoR2 and T‐cadherin . The different effects elicited by adiponectin are probably mediated by the distinct oligomers of this protein as well as by the different receptors .…”

Section: Introductionmentioning

confidence: 99%

Adiponectin profile at baseline is correlated to progression and severity of multiple sclerosis

Signoriello

Lus

Polito

et al. 2018

Euro J of Neurology

View full text Add to dashboard Cite

Background and purpose Adiponectin is a cytokine linking energy metabolism and immune system. After being assembled, adiponectin circulates as oligomers of different molecular weight, i.e. low, medium and high (HMW) molecular weight. These have the most potent biological effects. Multiple sclerosis (MS) is an autoimmune disease of the human central nervous system. The aim of this study was to characterize the expression levels of both total adiponectin and its oligomerization state in the serum from 99 patients with MS at baseline (i.e. not influenced by therapies). We also investigated the potential relationships between adiponectin and disease progression and severity. Methods Adiponectin was quantified and visualized by enzyme‐linked immunosorbent assay, western blotting and fast protein liquid chromatography. During the follow‐up (3.6 ± 2.20 years), the patients were evaluated using total annualized relapse rate and Expanded Disability Status Scale score. Results Total adiponectin is statistically higher in patients with MS compared with matched controls (12.18 vs. 10.02 μg/mL, P = 0.001). Interestingly, the adiponectin oligomerization state is altered in MS, with an increase of HMW oligomers. In addition, patients with MS with higher levels of adiponectin at baseline have significantly higher risk of progression and severity (Multiple Sclerosis Severity Score, 3.84 vs. 2.44, P = 0.001). No statistical difference in adiponectin expression was found between active and inactive patients with MS and among the different forms of disease. Conclusions This study demonstrated that adiponectin and its HMW oligomers are greatly involved in MS autoimmune disorder representing a potential biomarker to predict worse MS prognosis and severity. Further studies are required to clarify the molecular mechanisms underlying the properties of adiponectin and HMW oligomers in MS.

show abstract

The role of adiponectin receptors in the regulation of synaptic transmission in the hippocampus

Cited by 25 publications

References 57 publications

Role of Adiponectin in Central Nervous System Disorders

Role of Adiponectin in Central Nervous System Disorders

Adiponectin improves long-term potentiation in the 5XFAD mouse brain

Adiponectin profile at baseline is correlated to progression and severity of multiple sclerosis

Contact Info

Product

Resources

About